US 12,071,483 B1
Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof
Jinhyung Ahn, Seongnam-si (KR); Sungwon An, Seongnam-si (KR); Dongin Kim, Seongnam-si (KR); Eunsil Sung, Seongnam-si (KR); Jaehyun Eom, Seongnam-si (KR); Sang Hoon Lee, Seongnam-si (KR); Weonkyoo You, Seongnam-si (KR); Juhee Kim, Seongnam-si (KR); Kyungjin Park, Seongnam-si (KR); Hyejin Chung, Seongnam-si (KR); Jinwon Jung, Seongnam-si (KR); Bora Lee, Seongnam-si (KR); Byungje Sung, Seongnam-si (KR); Yeunju Kim, Seongnam-si (KR); Yong-Gyu Son, Seongnam-si (KR); Seawon Ahn, Seongnam-si (KR); Daehae Song, Seongnam-si (KR); Jiseon Yoo, Seongnam-si (KR); Youngdon Pak, Seongnam-si (KR); Donghoon Yeom, Seongnam-si (KR); Yoseob Lee, Seongnam-si (KR); and Jaeho Jung, Seongnam-si (KR)
Assigned to ABL BIO INC., Seongnam-si (KR)
Appl. No. 16/770,728
Filed by ABL Bio Inc., Seongnam-si (KR)
PCT Filed Dec. 14, 2018, PCT No. PCT/KR2018/015953
§ 371(c)(1), (2) Date Jun. 8, 2020,
PCT Pub. No. WO2019/117684, PCT Pub. Date Jun. 20, 2019.
Claims priority of provisional application 62/734,391, filed on Sep. 21, 2018.
Claims priority of provisional application 62/734,388, filed on Sep. 21, 2018.
Claims priority of provisional application 62/693,474, filed on Jul. 3, 2018.
Claims priority of application No. 10-2017-0172205 (KR), filed on Dec. 14, 2017.
Int. Cl. A61K 39/395 (2006.01); A61K 47/68 (2017.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 47/6845 (2017.08); C07K 16/18 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01)] 18 Claims
 
1. An anti-α-synuclein (α-syn)/anti-insulin-like growth factor 1 receptor (IGF1R) bispecific antibody, comprising:
a) an anti-α-syn antibody or an antigen binding fragment thereof; and
b) an anti-IGF1R antibody or an antigen binding fragment thereof comprising
i) a heavy chain variable region (VH) comprising
a heavy chain complementarity-determining region (CDR) 1 (H-CDR1) that comprises SEQ ID NO: 1,
an H-CDR2 that comprises SEQ ID NO: 13, and
an H-CDR3 that comprises SEQ ID NO: 52, and
ii) a light chain variable region (VL) comprising
a light chain CDR1 (L-CDR1) that comprises SEQ ID NO: 98,
an L-CDR2 that comprises SEQ ID NO: 117, and
an L-CDR3 that comprises SEQ ID NO: 152.